• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
  • Menu

New promising blood sugar pills for patients with type 2 diabetes

17.01.2018/in News /by X7 Research

The new pill form of semaglutide is considered to be promising and effective in controlling blood sugar levels in patients with type 2 diabetes. The scientists have finished a 26-week phase II clinical study and revealed that semaglutide showed statistically significant better glycemic control than a placebo. The paper was published in The Journal of the American Medical Association (JAMA) with the first author Dr. Melanie Davies of the Diabetes Research Centre at the University of Leicester in the United Kingdom. The obtained results provide a rationale for conducting phase III studies to evaluate the longer-term effects and safety of semaglutide in pill version.

It’s estimated that more than 90 percent of the 30 million people with diabetes in the US suffer from type 2 diabetes. To choose the best treatment option, doctors need to consider the complexity of the therapy and the possible risk of side effects, such as hypoglycemia or putting on weight. The authors believe that a pill form of semaglutide may be more suitable for some patients and therefore improve patient compliance and decrease the risk of complications.

For the phase II trial mentioned above, Dr. Davies and her colleagues included 632 patients with type 2 diabetes whose present therapy was not effective in terms of achieving adequate glycemic control. Thus, these patients had to take some actions in order to lower blood sugar, for example, do physical exercises or add-on metformin. The patients were randomized to different groups. Some groups were prescribed a daily pill form of semaglutide or a placebo, while others received a weekly injection of semaglutide. However, those patients who took the oral version of semaglutide were in groups that received different fixed daily doses or progressively increasing daily doses. Patients took medicines or placebo for 26 weeks. Glycosylated hemoglobin (HbA1c) level was the main outcome measure.

The researchers have demonstrated that the average alteration in HbA1c level over the 26 weeks of the trial fell in all the groups, with the major decrease in the patients who received semaglutide injections (1,9%). Though, all dosages of the oral version of semaglutide decreased average HbA1c (from -0,7 percent to -1,9%) significantly more than placebo (-0,3%) by the end of the trial. The authors have also found out that between 44–90% of patients who received the pill form of semaglutide (depending on dosage) achieved the target level of glycosylated hemoglobin (7%). What’s more, researchers have also demonstrated that 71 percent of patients who took the pill version of semaglutide achieved a “clinically relevant” weight loss of 5 percent or more. The side effects of taking the pill form were comparable to those of the parenteral form of semaglutide.

The authors have concluded: “These findings support phase III studies to assess longer-term and clinical outcomes, as well as safety.” The next possible step is to test the effects of oral semaglutide in patients with higher levels of HbA1c.

Source: medicalnewstoday.

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Readability User Testing of Package Information Leaflets (PIL) in EAEU
Read More
Publications
Remote clinical trial monitoring
Read More
Publications
Post-authorization studies of drug safety in Russia
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

1 + 7 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
New guide on good manufacturing practices for advanced therapies Reporting practices of drug studies results have improved
Scroll to top